FY2026 Earnings Estimate for MRK Issued By Erste Group Bank

Merck & Co., Inc. (NYSE:MRK) – Analysts at Erste Group Bank lifted their FY2026 earnings per share estimates for Merck & Co., Inc. in a report released on Tuesday, March 24th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $5.13 for the year, up from their prior estimate of $5.12. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $9.01 per share.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same period in the prior year, the company posted $1.72 earnings per share. Merck & Co., Inc.’s revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS.

Several other research analysts have also recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Merck & Co., Inc. in a report on Monday, December 29th. Bank of America boosted their price target on Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, December 15th. The Goldman Sachs Group increased their price target on Merck & Co., Inc. from $92.00 to $120.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd. Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. Finally, Guggenheim lifted their price objective on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $127.13.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $119.77 on Friday. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $296.13 billion, a P/E ratio of 16.45, a P/E/G ratio of 2.31 and a beta of 0.27. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The firm has a 50-day moving average price of $116.65 and a two-hundred day moving average price of $101.93.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of institutional investors have recently added to or reduced their stakes in MRK. J. Derek Lewis & Associates Inc. bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $214,000. Purpose Unlimited Inc. bought a new stake in Merck & Co., Inc. during the 4th quarter worth $11,048,000. Cornerstone Planning LLC bought a new stake in Merck & Co., Inc. during the 4th quarter worth $3,085,000. Rockefeller Capital Management L.P. grew its position in Merck & Co., Inc. by 33.2% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,722,146 shares of the company’s stock worth $181,274,000 after acquiring an additional 429,419 shares during the last quarter. Finally, Bank of New Hampshire grew its position in Merck & Co., Inc. by 3.1% during the 4th quarter. Bank of New Hampshire now owns 9,033 shares of the company’s stock worth $951,000 after acquiring an additional 275 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 37,685 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the transaction, the executive vice president owned 160,174 shares of the company’s stock, valued at approximately $19,368,240.08. The trade was a 19.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Michael Williams sold 5,000 shares of the stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $121.91, for a total transaction of $609,550.00. Following the completion of the transaction, the executive vice president directly owned 30,838 shares of the company’s stock, valued at $3,759,460.58. This trade represents a 13.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 320,176 shares of company stock valued at $38,281,735 over the last ninety days. 0.13% of the stock is owned by insiders.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced a US$6.7B acquisition of Terns Pharmaceuticals to add TERN-701 (an investigational oral CML therapy) to its oncology/hematology pipeline—a clear move to build revenue and R&D options ahead of Keytruda’s planned 2028 exclusivity loss. Merck Targets Post Keytruda Future With US$6.7b Terns Acquisition
• Positive Sentiment: RBC reiterated an Outperform and kept a $142 price target after Merck’s Terns call, signaling sell‑side support for the strategy despite questions about the transaction premium. RBC Reiterates Merck (MRK) Outperform
• Positive Sentiment: Agilent won FDA approval for the PD‑L1 22C3 companion diagnostic in esophageal/GEJ carcinoma, which can help identify patients for Keytruda treatment—supportive for near‑term uptake in that indication. Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx
• Positive Sentiment: High-profile bullish commentary (e.g., Jim Cramer) and option/trade ideas targeting MRK indicate elevated investor interest and constructive conviction in Merck as a defensive large‑cap pharma. Jim Cramer on Merck & Co.
• Neutral Sentiment: Analyst model tweaks are minor: Erste marginally raised FY2026 EPS estimates (from $5.12 to $5.13), reflecting limited near‑term changes to consensus earnings expectations. MarketBeat analyst update
• Neutral Sentiment: Coverage pieces note Merck has outperformed recently (stock up ~50% over six months); some articles offer tactical trade ideas (options/covered calls) that reflect market momentum rather than fundamental shifts. Merck Stock Soars 50% in 6 Months
• Negative Sentiment: Keytruda’s planned 2028 loss of exclusivity remains the central long‑term risk—analysts and articles stress patent cliff exposure and some weak vaccine sales, which temper valuation upside. Zacks: Merck Stock Soars 50% in 6 Months
• Negative Sentiment: The proposed Terns transaction may face rival interest and is the subject of a shareholder‑lawyer investigation (Kahn Swick & Foti), introducing deal execution, regulatory and legal risk that could delay or change terms. MSN: Merck’s Terns acquisition may face rival interest BusinessWire: KSF Investigation

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.